ASRM: Annual Meeting Final Program

BIOIDENTICAL HORMONES: SAFE CHOICE OR HIGH RISK FOR MENOPAUSE?
Chair: Cynthia K. Sites, M.D.
Presenters: John E. Buster, M.D. (Con) and Nanette F. Santoro, M.D. (Pro)

NEEDS ASSESSMENT
Bioidentical hormones, or those that match the chemical structure of those produced naturally by the body, have been promoted as safer and more effective than traditional menopausal hormones on clinical outcomes such as breast, endometrium, bone, and brain. Although patients are reading more in the lay literature about these products and asking their physicians to prescribe them, physicians often have little information about long-term safety and efficacy of these products. A greater understanding of the types and dosages of products available, FDA oversight of them, purity, and their safety and efficacy is needed.

LEARNING OBJECTIVES
At the conclusion of this debate, attendees should be able to:

List the evidence supporting the safety and efficacy of bioidentical estrogens and progesterone on breast, endometrium, bone, and brain.
Describe the possible risks of using bioidentical hormones.
Summarize the gaps in current knowledge about the use of bioidentical estrogens (estradiol, estrone, estriol) and progesterone.

MENOPAUSE WORKSHOP
Room 201
11:00 a.m. - 12:00 p.m.

MOCK TRIAL: MY BIOIDENTICAL ESTRIOL AND PROGESTERONE CAUSED MY BREAST CANCER

Judge: Cynthia K. Sites, M.D. Jury: Audience
Plaintiff Attorney: David H. Barad, M.D.
Defense Attorney: John F. Randolph, Jr., M.D.
Plaintiff: Karen D. Bradshaw, M.D.
Defendant: Johanna S. Archer, M.D.

NEEDS ASSESSMENT
Bioidentical hormones, including estradiol, estrone, estriol, and progesterone, have been used in Europe in the past and are now becoming more popular in the United States partly due to increased publicity in the lay press. Women often ask their physicians to prescribe such compounds, and compounding pharmacies are willing to participate. Risks and benefits of these compounds, in particular the risk of breast cancer, is not well understood and will be examined in a mock trial setting.

LEARNING OBJECTIVES
At the conclusion of this mock trial, attendees should be able to:

List evidence, pro and con, regarding the possible association of bioidentical hormones use and breast cancer risk.
Summarize the evidence regarding use of salivary hormone assays in monitoring levels of bioidentical hormones in post menopausal women.
As part of the jury, evaluate the evidence presented to determine if, within a reasonable degree of medical certainty, the bioidentical hormones in this case caused breast cancer.

MENOPAUSE DAY ROUNDTABLES:
Hall E
12:15 p.m. - 1:15 p.m.

MONDAY

M28. PHYTOESTROGENS AND THE CLIMACTERIC • Cynthia K. Sites, M.D.

M29. RACE, ETHNICITY, AND MENOPAUSAL SYMPTOMS: APPROACH TO TREATMENT • David H. Barad, M.D.

M30. ASSOCIATION OF PELVIC ORGAN PROLAPSE AND FRACTURE • Lubna Pal, M.D.

M31. HORMONE TREATMENT AND ENDOMETRIAL SAFETY: PROGESTERONE IN THE BALANCE • Veronica A. Ravnikar, M.D.

M32. ANDROGEN REPLACEMENT AFTER MENOPAUSE • Peter R. Casson, M.D.

MENOPAUSE DAY KEYNOTE SPEAKER
Room 201
1:30 p.m. - 2:15 p.m.

THE WHI HORMONE THERAPY TRIALS: MAKING SENSE OF THE EVIDENCE
JoAnn E. Manson, M.D., Dr.P.H.

BREAK 2:15 p.m. - 3:00 p.m.

MENOPAUSE ORAL ABSTRACT PRESENTATIONS
Room 201
3:00 p.m. - 5:00 p.m.

MENOPAUSE SIG MEMBERS MEETING
Room 201
5:00 p.m. - 5:30 p.m.

MENOPAUSE POSTER PRESENTATIONS & RECEPTION
Hall E
5:30 p.m. - 7:00 p.m.

Return to the Final Program

By accessing and using the ASRM Web Site, you agree to be bound by
the ASRM Web Site Terms and Conditions of Use.

View the ASRM Non Discrimination Policy

Listed on Infertility Resources
Developed and hosted by Internet Health Resources

ASRM 2007 Annual Meeting

Menopause Day Monday, October 15, 2007

Menopause Day
Monday, October 15, 2007